JUNOVAN

Welcome to the Brand page for “JUNOVAN”, which is offered here for Preparations for medical or veterinary use, muramyl peptides and muramyl tripeptides, muramyl tripeptide phosphatidyl ethanolamine (mtp-pe), n-acetylmuramyl-l-ananyl-d-isoglutaminyl-l-alanine-2 (l,2-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy) ethylamide, hexopyranose and formulations of muramyl peptides, particularly liposomal formulations, pharmaceutically acceptable forms of muramyl peptides, pharmaceutically acceptable salts of muramyl peptides, all these goods specifically used for cancer control treatment, antiviral treatment, neoplasia and pathologies induced by chemotherapy, particularly mucositis, myelosuppression, peripheral neuropathy; pharmaceutical preparations for anti-cancer and antiviral therapies, neoplasia and pathologies induced by chemotherapy, particularly mucositis, myelosuppression, peripheral neuropathy;.

Its status is currently believed to be active. Its class is unavailable. “JUNOVAN” is believed to be currently owned by “I.D.M. IMMUNO-DESIGNED MOLECULES”.


Owner:
I.D.M. IMMUNO-DESIGNED MOLECULES
Owner Details
Description:
Preparations for medical or veterinary use, muramyl peptides and muramyl tripeptides, muramyl tripeptide phosphatidyl ethanolamine (MTP-PE), N-acetylmuramyl-L-ananyl-D-isoglutaminyl-L-alanine-2 (l,2-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy) ethylamide, hexopyranose and formulations of muramyl peptides, particularly liposomal formulations, pharmaceutically acceptable forms of muramyl peptides, pharmaceutically acceptable salts of muramyl peptides, all these goods specifically used for cancer control treatment, antiviral treatment, neoplasia and pathologies induced by chemotherapy, particularly mucositis, myelosuppression, peripheral neuropathy; pharmaceutical preparations for anti-cancer and antiviral therapies, neoplasia and pathologies induced by chemotherapy, particularly mucositis, myelosuppression, peripheral neuropathy;
Categories: PREPARATIONS MEDICAL OR VETERINARY